Skip to content
Global sound
Citeline Podcasts

Citeline Podcasts

Strategic Intent: Praxis CEO On Unlearning, AI And Launching Two Neuroscience Drugs At Once

· 45 min

Show notes

Praxis Precision Medicines is within weeks of FDA decisions on two potential firsts: relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies, and ulixacaltamide for essential tremor. In this episode of Strategic Intent, In Vivo senior reporter David Wild talks with Praxis CEO Marcio Souza about the company’s philosophy of “unlearning,” how AI is embedded across the organization, and why he believes neurology is entering its own precision medicine era. Souza also explains how Praxis is preparing to launch two very different products at once, how he led the team through the vormatrigine setback, and what it takes to build a next-generation CNS company. Subscribe to the In Vivo and Scrip channels for more Strategic Intent.

Live, last hour: 11,631 songs on 4,541 stations in 113 countries

Discover the world through radio

More ways to discover (7)

Heard something good? Save it, or open it straight away in Spotify.

★ Artist of the week The fastest riser on the radio this week
Your song here? From € 9 per week →
KALC Alice 105.9Continue listening